[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351468-105":59,"doc-detail-351468-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","preclinical-combination-targeting-vegf-and-pi3k-in-a-rare-aggressive-mixed-endometrial-carcinoma-an-applied-case-report","Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma - An Applied Case Report","","Rare, aggressive mixed endometrial carcinoma developed after endocrine treatment in a young patient (VENUS 167). The case used progression tissue to generate OPTO.85, a patient-derived organoid (PDO) and corresponding organoid-derived xenograft (ODX), and multi-omic analyses showed OPTO.85 faithfully mirrored tumor features. Whole-exome sequencing found oncogenic alterations in PIK3CA, ARID1A, and CTNNB1, while RNA-seq and ATAC-seq indicated enriched VEGF and Wnt pathways. High-throughput drug screening identified PI3K and VEGF vulnerabilities: PI3K inhibitor sensitivity and cediranib synergy with BKM120 reduced growth in vitro and suppressed tumors in vivo, supporting genomic profiling and patient-derived models for actionable targets.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-combination-targeting-vegf-and-pi3k-in-a-rare-aggressive-mixed-endometrial-carcinoma-an-applied-case-report/351468/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-combination-targeting-vegf-and-pi3k-in-a-rare-aggressive-mixed-endometrial-carcinoma-an-applied-case-report/351468.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What models were created from the patient’s tumor in the study?","Question",{"text":113,"@type":114},"The researchers generated OPTO.85, a patient-derived organoid (PDO), and a corresponding organoid-derived xenograft (ODX) from progression tumor tissue.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which genetic alterations were identified in OPTO.85?",{"text":118,"@type":114},"Whole-exome sequencing identified oncogenic alterations in PIK3CA, ARID1A, and CTNNB1.",{"name":120,"@type":111,"acceptedAnswer":121},"How did VEGF and PI3K inhibition perform in experiments?",{"text":122,"@type":114},"OPTO.85 showed sensitivity to PI3K inhibitors, and cediranib demonstrated synergy with BKM120, significantly reducing organoid growth and suppressing tumor growth in the ODX model compared with single agents.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351468,1790788492,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0634](https://doi.org/10.1158/2767-9764.CRC-25-0634)  OPEN ACCESS  \nPreclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report  \nNikolina Radulovich, Pamela Soberanis Pina, Molly L. Udaskin, Quan Li, Kevin C.J. Nixon, Irene Y. Xie, Ankita Nand, Joshua C. Rosen, Ming Li, Anjelica Hodgson, Nhu-An Pham, Amit M. Oza, Mathieu Lupien, Robert Rottapel, Ming-Sound Tsao, and Stephanie Lheureux  \n􀀶  \nABSTRACT  \nWe report a rare case of a young patient (VENUS 167) initially diagnosed with grade 1 endometrioid endometrial cancer, which, following endocrine treatment, presented with mixed aggressive carcinoma with three distinct histologic patterns: grade 1 endometrioid, large cell neuroendocrine, and undifferentiated carcinoma. The surgical specimen at the time of disease progression was used to establish OPTO.85, a patient-derived organoid (PDO), followed by a corresponding organoid-derived xenograft (ODX). Multi-omic analyses confirmed that OPTO.85 accurately reflected the patient’s tumor characteristics. Whole-exome sequencing analysis identified oncogenic alterations in PIK3CA, ARID1A, and CTNNB1. Further RNA sequencing and assay for transposase-accessible chromatin using sequencing analyses revealed enrichment in VEGF and Wnt signaling pathways, suggesting therapeutic vulnerabilities. A high-throughput drug screen was conducted using ApexBio-approved and epigenetic drug libraries, along with kinase inhibitor and tool compound libraries developed at the Ontario Institute of Cancer Research. The OPTO.85 PDO exhibited  \nsensitivity to PI3K inhibitors and responsiveness to VEGF inhibition. Cediranib demonstrated synergy with BKM120, significantly reducing  \norganoid growth. This combination also showed in vivo efficacy in the ODX model, in which dual inhibitors significantly suppressed tumor growth compared with single compounds. This case exemplifies the impact of genomic profiling and patient-derived models in identifying actionable molecular changes in rare cancers with limited therapeutic options and poor prognosis. It highlights that high-throughput sequencing for individual patient tumors and generation of patient-derived models are feasible in endometrial cancer. This preclinical model may assist clinical decision and personalized therapy requiring validation in prospective studies.  \nSignificance: This study characterizes a rare aggressive mixed endometrial carcinoma that developed after hormonal therapy. Patient-derived organoid and xenograft models revealed actionable targets in the VEGF and PI3K pathways. Combined cediranib and BKM120 treatment showed synergistic antitumor effects in vitro and in vivo. These findings  \nhighlight the potential of integrating molecular profiling and drug testing to guide personalized therapies in rare and recurrent endometrial cancers.  \nIntroduction  \nEndometrial cancer is the most common cancer of the female reproductive organs, encompassing a heterogeneous group of subtypes with distinct features and outcomes ( 1, 2) . Recent advances in molecular profiling have improved risk stratification in endometrial cancer through the development of surrogate molecular subgroups defined by the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) framework. These include  \nOntario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.  \nCorresponding Author: Stephanie Lheureux, Princess Margaret Cancer Centre, 700 University Avenue, Suite 7-823, Toronto M5G 1Z5, Canada. E-mail:  \n[stephanie.lheureux@uhn.ca](stephanie.lheureux@uhn.ca)  \ndoi: 10.1158/2767-9764.CRC-25-0634  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the American Association for Cancer Research  \nPOLE-mutated, mismatch repair (MMR)-deficient, p53-abnormal, a","cbCairwRDXmHQJOJ","https://ap.wps.com/l/cbCairwRDXmHQJOJ","pdf",18123973,"English","# Abstract\n# Significance\n# Introduction\n# Materials and Methods","[{\"question\":\"What models were created from the patient’s tumor in the study?\",\"answer\":\"The researchers generated OPTO.85, a patient-derived organoid (PDO), and a corresponding organoid-derived xenograft (ODX) from progression tumor tissue.\"},{\"question\":\"Which genetic alterations were identified in OPTO.85?\",\"answer\":\"Whole-exome sequencing identified oncogenic alterations in PIK3CA, ARID1A, and CTNNB1.\"},{\"question\":\"How did VEGF and PI3K inhibition perform in experiments?\",\"answer\":\"OPTO.85 showed sensitivity to PI3K inhibitors, and cediranib demonstrated synergy with BKM120, significantly reducing organoid growth and suppressing tumor growth in the ODX model compared with single agents.\"}]","Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma - An Applied Case Report | PDF",1790094308,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c5bb824e5b19bb0d9479f3b05140466.webp",983,1263,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1335e261edb86f307f369a7e26ca620c.webp",982,1262,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e1b3fb1cb94eec3d5dbdfee984935a7.webp",981,1261,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10d202976247999ca308b50ad5746246.webp",980,1259]